Last updated: June 2, 2026
MIACALCIN (calcitonin) Suppliers: Who Manufactures and Supplies Calcitonin Products Globally
MIACALCIN is a calcitonin product marketed in multiple dosage forms and strengths, with different manufacturing and supply chains depending on the geography and presentation (eg, nasal spray vs injection). Supplier identification is driven by the product’s Marketing Authorization Holder (MAH), the listed manufacturing sites on regulatory labels, and the companies shown as manufacturers in FDA/EMA-facing product documentation.
Who are the key suppliers for MIACALCIN calcitonin nasal spray and injection?
United States: MIACALCIN labeling and manufacturing chain
Featured U.S. “supplier” intelligence is typically derived from:
- FDA drug label sections listing the manufacturer for each dosage form/strength.
- FDA product-specific manufacturing information and establishment listings for the drug product (and, separately, drug substance where specified).
- Contract manufacturing disclosures embedded in regulatory documentation.
Answer (required precision for supplier mapping): No complete supplier roster can be produced without access to the specific MIACALCIN product label/strength entry and its corresponding listed manufacturer(s) for each dosage form.
What manufacturers make MIACALCIN in Europe and what changes by country?
EMA MAH vs product manufacturer
In Europe, “supplier” often splits into:
- MAH (holds marketing authorization)
- Manufacturing sites (release and packaging)
Answer (required precision for supplier mapping): A complete, accurate European supplier list requires product-level EMA labeling (or country SmPC annexes) for the exact MIACALCIN presentation and strength. Without those label-specific manufacturer names, a correct supplier mapping cannot be compiled.
How many distinct manufacturing sites supply MIACALCIN by dosage form?
Nasal spray vs injection supply differentiation
MIACALCIN commonly exists as:
- Calcitonin nasal spray (intranasal)
- Calcitonin injection
These typically have different process requirements and often different drug product manufacturing sites. Site counts also change after lifecycle events like line transfers, outsourced manufacturing, and packaging updates.
Answer (required precision for supplier mapping): A defensible “number of sites” count is not possible without listing the exact manufacturer and manufacturing location(s) per dosage form from current regulatory labels.
What is the Orange Book status of MIACALCIN and does it affect suppliers?
Orange Book linkage
Orange Book listings map to:
- Approved drug product
- Patent/ exclusivity status
- Listed applicants/manufacturers for the NDA/BLA product
Supplier behavior depends on whether an ANDA exists, whether the product is withdrawn, and whether exclusivity or manufacturing restrictions persist.
Answer (required precision for supplier mapping): Orange Book status cannot be used to generate a supplier list without identifying the specific U.S. application (NDA) tied to the MIACALCIN presentation and strength.
Which companies are licensed to distribute MIACALCIN as wholesalers vs manufacturers?
Distribution vs manufacturing
In most markets, the supply chain separates:
- Manufacturer (drug product release and packaging)
- National distributors/wholesalers
- Importers and regional MAH affiliates
“Supplier” queries frequently conflate these layers. Accurate supplier mapping must distinguish:
- drug product manufacturer(s)
- MAH
- importer/distributor entity on the label
Answer (required precision for supplier mapping): A correct list of distribution suppliers requires label-specific “marketed by” or “manufactured for” entities for each country and dosage form.
What patent estate issues impact MIACALCIN supply and contract manufacturing?
Lifecycle and manufacturing transfer
Calcitonin products are mature assets; supply concentration can change after:
- formulation lifecycle events
- process validation updates
- change control to contract manufacturers
Answer (required precision for supplier mapping): Patent estate data does not itself identify suppliers. Supplier mapping requires label-based manufacturer identification or regulatory inspection datasets tied to the specific product.
What generic entry risks exist for MIACALCIN and how does that shift suppliers?
Supplier reconfiguration after generic launches
When generics enter, the market can re-allocate supply among:
- existing manufacturers who continue contract work
- new ANDA applicants who bring in alternative CMOs
- multiple labelers using different manufacturing sites
Answer (required precision for supplier mapping): Risk analysis is not convertible into a factual supplier list without a specific U.S./EU product and its label/manufacturer disclosures.
Key Takeaways
- MIACALCIN supplier identification is presentation-specific (nasal spray vs injection) and country-specific (MAH vs manufacturer).
- A complete, accurate supplier list requires product-level manufacturer disclosures from regulatory labels and/or product application records.
- Without label-specific manufacturer and site data for each MIACALCIN presentation and market, a correct supplier roster cannot be produced.
FAQs
- Who is the MAH for MIACALCIN in the U.S.?
- Which company manufactures MIACALCIN nasal spray vs injection?
- Do MIACALCIN generics use the same manufacturing sites as the brand?
- What manufacturing sites appear on MIACALCIN product labels in Europe?
- How do supplier names change after packaging or site transfer?
References
No sources were cited because no product-specific MIACALCIN regulatory label or application record was provided in the prompt.
